fr   en
Clinical Studies
Phase :    
Announcement :   
Select a Pharma :
Select a product :
Select a disease :
Choose date:
[<<]      «      46   |   47   |   48   |   49   |   50   |   51   |   52   |   53   |   54   |   55   |   56      »      [57]
Date Phase Anouncement Biotech Pharma Product Disease Country Other
2007-04-10 I Launch Neuropharma (Zeltia Group - Spain) - On September 10, 2008, Neuropharma changed its name to Noscira.   NP 61 (orally bioavailable acetylcholinesterase inhibitor and â-amyloid modulator) Alzheimer's disease UK See details
2007-04-10 I Launch Neurosearch (Denmark) Astellas Pharma (Japan) ACR16 (dopamine stabiliser) schizophrenia USA See details
2007-04-10 I Launch NeuroPharma (Spain)   NP-61 Alzheimer's disease United Kingdom See details
2007-04-03 III Launch Nicox (France)   Naproxcinod Knee arthrosis USA See details
2007-04-02 I Launch Nautilus Biotech (France)   Belerofon® (interferon alpha with a prolonged half-life) Several potential indications, including the treatment of hepatitis C USA See details
2007-03-27 II Launch Topotarget (Denmark)/Curagen (USA)   belinostat (PXD101 - histone deacetylase inhibitor) Multiple myeloma USA See details
2007-03-27 II Launch Nicox (France) Pfizer (USA) PF-03187207 Glaucoma, ocular hypertension.   See details
2007-03-26 II Launch Chroma Therapeutics (UK)   CHR-2797 (the product was originally licensed from Vernalis). refractory acute myeloid   See details
2007-03-22 I Launch Evotec (Germany)   EVT 302, monoamine oxidase B inhibitor (IMAO-B) Smoking cessation.   See details
2007-03-12 I Launch Symphogen (Denmark)/Biovitrum (Sweden)   Sym001 (polyclonal anti-Rhesus D antibody) The target indications are the prevention of neonatal haemolytic syndrome and the treatment of idiopathic thrombocytopenic purpura. USA See details
2007-03-08 I-II Launch 7TM Pharma (Denmark)   TM30339 (selective Y4 receptor agonist) obesity   See details
2007-02-23 III Result   UCB (Belgium) Cimzia® (certolizumab pegol - CDP 870) rheumatoid arthritis   See details
2007-02-13 I Launch Transgene (France)   TG4040 (MVA-HCV, MVA virus carrying and expressing non structural proteins (NS3, NS4 et NS5B) of the hepatitis C virus) hepatitis C France See details
2007-02-08 I Launch Innate Pharma (France) Novo Nordisk (Denmark) IPH 2101 acute myeloid leukaemia The France-based phase I trial intended to evaluate the compound's tolerance in humans is performed jointly at the Institut Gustave-Roussy (Villejuif) and the Institut Paoli-Calmettes (Marseilles). See details
2007-02-05 II Result Actelion (Switzerland)   ACT-078573 (derivative of tetrahydroisoquinolyl-acetamide, an orexin antagonist) chronic insomnia   See details
[<<]      «      46   |   47   |   48   |   49   |   50   |   51   |   52   |   53   |   54   |   55   |   56      »      [57]